What is Mologic?
Mologic operates as a specialized developer of rapid diagnostic products, leveraging a sophisticated technological framework that spans human healthcare and veterinary medicine. Since re-establishing its independence in 2014, the firm has cultivated a diverse product pipeline, achieving notable regulatory milestones including CE mark approvals. Beyond its proprietary product development, Mologic functions as a high-value contract partner, providing end-to-end services that encompass reagent supply, product design, and ISO13485-certified manufacturing. By harmonizing these capabilities, the company effectively manages the entire product lifecycle, from initial conceptualization to pre-market evaluation and eventual global distribution.
How much funding has Mologic raised?
Mologic has raised a total of $14.9M across 4 funding rounds:
Private Equity
$4.6M
Series A
$4.6M
Grant
$4.8M
Series B
$915K
Private Equity (2015): $4.6M with participation from Calculus Capital
Series A (2015): $4.6M led by Calculus Capital
Grant (2016): $4.8M supported by Bill & Melinda Gates Foundation
Series B (2018): $915K featuring Innovate UK
Key Investors in Mologic
Bill & Melinda Gates Foundation
A global philanthropic organization dedicated to enhancing healthcare outcomes and reducing extreme poverty through strategic investments in medical research and technology.
Calculus Capital
A London-based investment manager focused on providing tax-efficient growth capital to high-potential UK businesses within the healthcare and technology sectors.
Innovate UK
The UK government's innovation agency, tasked with supporting business-led research and development to drive economic growth through technological advancement.
What's next for Mologic?
With the support of its latest capital injection, Mologic is poised to scale its operational capacity and finalize the launch of its highly anticipated respiratory disease exacerbation monitor. The strategic focus remains on expanding its footprint in both human and animal health sectors, utilizing its advanced diagnostic platforms to address unmet clinical needs. As the company transitions into a phase of high-volume manufacturing and international market penetration, it will likely continue to leverage its professional partnerships to navigate complex regulatory environments. This growth phase is expected to solidify Mologic's reputation as a leader in diagnostic innovation, ensuring that its technological advancements reach global markets with the necessary scale and precision.
See full Mologic company page
